Regeneron Pharmaceuticals And Sanofi Today Announced That National Medical Products Administration In China Has Approved Dupixent (Dupilumab) As An Add-on Maintenance Treatment For Adults With Uncontrolled Chronic Obstructive Pulmonary Disease
Regeneron Pharmaceuticals And Sanofi Today Announced That National Medical Products Administration In China Has Approved Dupixent (Dupilumab) As An Add-on Maintenance Treatment For Adults With Uncontrolled Chronic Obstructive Pulmonary Disease
再生元製藥公司和賽諾菲安萬特今天宣佈，中國國家藥品監督管理局已批准Dupixent（Dupilumab）作爲一種成人未受控制的慢性阻塞性肺疾病的附加維持治療。
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life.
Dupixent已獲歐盟批准用於COPD患者，這些患者患有升高的血液嗜酸性粒細胞，該批准基於兩項具有里程碑意義的III期臨床試驗證明Dupixent顯著減少惡化次數，改善肺功能，並改善了相關健康生活質量。
COPD is the most prevalent chronic respiratory disease in China, and is a priority within the government's Healthy China 2030 public health plan.
COPD是中國最常見的慢性呼吸系統疾病，在政府《健康中國2030》公共衛生計劃中屬於重點關注領域。
Dupixent is now approved in four indications across respiratory and dermatological diseases in China.
Dupixent目前已在中國獲得四項呼吸系統和皮膚病的適應症批准。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間